Article Text

Download PDFPDF
Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants
  1. M Langgartner,
  2. A Mutenthaler,
  3. N Haiden,
  4. A Pollak,
  5. A Berger
  1. Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
  1. Dr Michaela Langgartner, Medical University of Vienna, Department of Paediatrics and Adolescent Medicine, Waehringer Guertel 18–20, 1090 Vienna, Austria; michaela.langgartner{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Ventriculostomy-related cerebrospinal fluid (CSF) infection remains a major problem in neonatal intensive care. The spectrum of pathogens causing these infections is dominated by coagulase-negative staphylococci, and vancomycin is the antibiotic of choice for treatment. However, vancomycin is known to have only poor penetration into the CSF when applied intravenously and is therefore being applied intraventricularly.1

The oxazolidinone linezolid has antibacterial activity against most drug-resistant Gram-positive bacteria and has been shown to have excellent penetration into the CSF in adults.2 Trials on the pharmacokinetics and …

View Full Text


  • Competing interests: None.